Profound Medical Corp. (PROF) は上場企業です ヘルスケア セクターの Medical - Devices 業界で事業展開. 本社所在地は Mississauga, ON, カナダ. 現CEOは Arun Swarup Menawat.
PROF を有する IPO日 2019-10-29, 142 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $194.27M.
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
